VU University Medical Center, Amsterdam, the Netherlands;
Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology, Zurich;
Research Laboratories of Schering AG, Berlin, Germany;
Istituto G. Gaslini, Genova, Italy
Objective: The human monoclonal antibody L19-SIP is directed against the extra domain B of fibronectin (ED-B), a marker of tumor angiogenesis. The potential of radioimmunotherapy (RIT) with L19-SIP was evaluated, either alone or in combination with the anti–epidermal growth factor receptor (EGFR) antibody cetuximab, for treatment of head and neck squamous cell carcinoma (HNSCC).
Tijink BM, Neri D, Budde M, Leemans CR, Dinkelborg LM, Stigter-van Walsum M, Zardi L, van Dongen GAMS. P104 Radioimmunotherapy of Head and Neck Cancer Xenografts Using 131I-L19-SIP for Selective Targeting of Tumor Vasculature. Arch Otolaryngol Head Neck Surg. 2006;132(8):886. doi:10.1001/archotol.132.8.886-a